Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
The Phase 1/2/3 trial to be funded and sponsored by Arcturus’ manufacturing partner Vinbiocare ARCT-154…